Chemotherapy-associated peripheral neuropathy
Conditions
Interventions
Control Group:Oral Methylcobalamin tablets, 0.5 mg per tablet, three times daily, one tablet each time, for a 4-week course.
Treatment group:Zhu Lian Excitation Type II Needle Method for Treatment
Sponsors
Guangxi Medical University Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Patients who develop symptoms of peripheral neuropathy after chemotherapy and meet the diagnostic criteria; (2) Patients with a confirmed diagnosis of malignant tumors who have undergone chemotherapy; (3) Patients aged over 18 years and under 80 years; (4) Patients with an expected survival period of =6 months; (5) Patients with normal biochemical indicators, no severe organic damage, and no coagulation or hematopoietic dysfunction; (6) Patients with a Karnofsky score =70 (Karnofsky Performance Status Scale: the higher the score, the better the health status); (7) Patients with good compliance, who understand the treatment process, and who agree to and sign the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Those with obvious damage to heart, liver, kidney, or hematopoietic function; mentally ill patients; pregnant or breastfeeding women; (2) Patients with a history of skin allergic diseases; (3) Patients with hand or foot injuries, ulcers, or infections; (4) Patients with diabetes complicated by peripheral nerve damage; (5) Subjects currently participating in other drug trials; (6) Subjects deemed unsuitable for this trial by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - Neurotoxicity; | — |
Secondary
| Measure | Time frame |
|---|---|
| Electromyography (EMG) measurement of nerve conduction velocity;Peripheral Neurotoxicity Grading; | — |
Countries
China
Contacts
Public ContactNie Yingjie
Guangxi Medical University Cancer Hospital
Outcome results
None listed